GU Cancers 2019 | Enfortumab vedotin as treatment for urothelial carcinomas

Daniel Petrylak

Prof. Daniel Petrylak, MD, from the Yale Cancer Center, New Haven, CT, discusses the promising results of enfortumab vedotin clinical trials, including the Phase III EV-301, where patients with urothelial cancer are administered the antibody-drug complex. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Petrylak explains that enfortumab vendotin is effective whether or not the patient has previously received checkpoint-inhibitor therapy. Prof. Petrylak then moves on to speak about side effects and the constructs toxicity profile.

Share this video